← Evidence map

ArticleCancers2022

Glofitamab Treatment in Relapsed or Refractory DLBCL after CAR T-Cell Therapy.

Vera Rentsch et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

31 papers cite it

2022
2023
2024
2025
2026
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 35626120